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Abstract
The American Heart Association considers device-
guided breathing as a reasonable treatment modality 
in their statement on non-pharmacological options 
for lowering blood pressure. This review discusses all 
randomized controlled trials that have investigated the 
effects of device-guided breathing on blood pressure 
in patients with hypertension. Thirteen studies were 
included in this review. In total, 627 patients were in-
cluded, of which 365 patients were allocated to device-
guided breathing. Only 6 studies used acceptable 
control groups: listening to music, meditative relaxa-
tion exercises, or a sham-device. Two sponsored trials 
showed beneficial effects of device-guided breathing, 
both used listening to music as a control group. The 
remaining 4 studies, which had no employees of the 
manufacturer listed as co-author, observed no benefi-
cial effects on blood pressure. There is only 1 study 
that used a sham device as a control group. All other 
studies were to some extend methodologically flawed. 
Based on the studies with an acceptable methodologi-
cal quality, there is no clear evidence supporting a 
short-term beneficial effect on blood pressure by using 
device-guided breathing.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: This review discusses all randomized control-
led trials that have investigated the effects of device-
guided breathing on blood pressure. There were 6 
studies with an acceptable control group. Two (manu-
facturer sponsored) trials showed beneficial effects of 
device-guided breathing, both used listening to music 
as a control group. The remaining 4 studies observed 
no beneficial effects. We conclude that there is no suffi-
cient evidence for recommending device-guided breath-
ing in the treatment of hypertension.
van Hateren KJ, Landman GW, Logtenberg SJ, Bilo HJ, Kleef-
stra N. Device-guided breathing exercises for the treatment of 
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INTRODUCTION
Treatment of  hypertension includes both pharmacologi-
cal and non-pharmacological interventions. Accepted 
non-pharmacological interventions are sodium restric-
tion, losing weight, increasing physical activity, smoking 
cessation and optimizing alcohol consumption[1-3]. In a 
scientific statement from the American Heart Associa-
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tion (AHA) regarding non-pharmacological options for 
lowering blood pressure, device-guided slow breathing is 
described as a reasonable treatment modality to reduce 
blood pressure (Class ⅡA, Level of Evidence B)[4]. Device-
guided slow breathing aims at lowering the respiratory 
frequency into a so-called “therapeutic breathing zone”
(less than 10 breaths per minute) through biofeedback 
by using an electronic device. Exercises are regarded as 
successful if  the total exercise time is at least 45 min per 
week, preferably 15 min daily[4]. Sympathetic overactiv-
ity is hypothesized as an important contributing factor 
in the development of  hypertension[5-7]. Efforts aimed at 
reducing this autonomic imbalance may indeed be an ef-
fective therapy for hypertension. Slow and regular breath-
ing, guided by musical tones, will lead to a reduction of  
sympathetic activity and also to an increase in heart rate 
variability[5]. The baroreceptors measure blood pressure 
in the carotid arteries and the aorta, and an increase in 
pressure leads to parasympathetic activation and vice 
versa (negative feedback mechanism). As an increase in 
heart rate variability will lead to an increased baroreflex 
sensitivity[5], device-guided breathing may lead to lower 
blood pressure values. 
The conclusions of  the writing group of  the AHA 
statement were based on a meta-analysis[8] and several 
other studies[9-19]. After the publication of  the guideline, 
two additional studies have been published[20,21]. The 
overall effect estimate in the meta-analysis showed a 
small beneficial blood pressure lowering effect [a reduc-
tion of  3.7 mmHg in systolic blood pressure (SBP)], but 
the authors of  the meta-analysis stated that the results 
of  the overall effect estimates should be interpreted with 
caution because of  methodological flaws in most studies. 
Beneficial effects were not observed after excluding stud-
ies with high risk of  bias or studies that were sponsored 
by or involved the manufacturer of  the device[8]. A pre-
vious editorial already emphasized that an independent 
double-blind study with a proper control group, prefer-
ably a sham device, would be necessary to answer the 
question whether device-guided breathing has any effect 
on blood pressure[22]. Recently, an investigator-initiated 
double-blind and sham-controlled trial was performed[20]. 
This review discusses all randomized controlled trials 
(RCTs) that have investigated the effects of  device-guid-
ed breathing on blood pressure in patients with hyperten-
sion.
PREVIOUS STUDIES
Thirteen studies, of  which the study and patient charac-
teristics are presented in Table 1, were included in this 
review. In total, 627 patients were included, of  which 
365 patients were allocated to device-guided breathing. 
Except for 1 study in which a bi-level positive pressure 
device (BiPAP®) was used[19], all other studies used the 
Resperate® device. The Resperate® device uses a form 
of  biofeedback with “breathe in” and “breathe out” 
instructions according to the listeners breathing rate to 
guide the respiration into a lower frequency by prolong-
ing expiration. The BiPAP® device was used for the 
treatment of  patients with obstructive sleep apnea and 
it was also capable of  guiding patients’ respiratory rate 
to less than 10 breaths per minute. Three studies had no 
control group[11,12,19], 4 studies compared the interven-
tion to usual care or frequent blood pressure measure-
ments[13,14,17,21], 4 studies compared the intervention to 
listening to music[9,10,15,16], 1 study compared the interven-
tion to meditative relaxation exercises[18], and 1 study used 
a sham-device in the control group[20]. Except for 3 stud-
ies[15,16,20], all other studies were sponsored by or involved 
the manufacturer of  the Resperate® and BiPAP® devices. 
According to the meta-analysis by Mahtani et al[8], the 
Anderson paper was also not sponsored by the manufac-
turer[18]. However, the acknowledgements section of  this 
manuscript states that Drs. B. Gavish, an employee of  the 
company that manufactures the Resperate® device, had 
reviewed the paper. 
EFFECTS OF DEVICE-GUIDED 
BREATHING
Table 1 presents an overview of  the effects of  device-
guided breathing on blood pressure. Only 4 studies 
reported between-group-differences including the 95% 
confidence intervals[9,15,16,20]. Significant decreases in blood 
pressure were observed in all 3 studies without a control 
group[11,12,19]. A significant between-group-difference was 
observed in 2 out of  4 studies that compared device-
guided breathing to daily blood pressure measure-
ments[13], and usual care[17]. Studies comparing device-
guided breathing to usual care cannot differentiate the 
3 possible mechanisms through which the Resperate® 
could have a blood pressure lowering effect: (1) effects 
of  guided slowing of  breathing itself; (2) listening to mu-
sic; and (3) sitting still. Conclusions regarding the isolated 
effect of  device-guided breathing are only valid when a 
study has an appropriate control group to disentangle 
these 3 effects. Therefore, this review will further focus 
on the 6 studies that used acceptable control groups: 
listening to music, meditative relaxation exercises and 
a sham-device[9,10,15,16,18,20]. Two sponsored trials showed 
beneficial effects of  device-guided breathing, both used 
listening to music as a control group[9,10]. In the study by 
Schein et al[9] device-guided breathing was not effective in 
lowering SBP compared to the control group. This study 
pre-defined a 5 mmHg reduction in diastolic blood pres-
sure (DBP) as clinically relevant. The difference in DBP 
change between both groups was 4.4 mmHg in favour of  
the intervention group (P = 0.008). Although a second 
study failed to predefine a clinically relevant difference, it 
showed a significant decrease in office SBP compared to 
a Walkman group (between-group-difference 4.6 mm Hg, 
P = 0.001)[10]. The remaining 4 studies, which had no em-
ployees of  the manufacturer listed as co-author, observed 
no beneficial effects on blood pressure[15,16,18,20]. Only the 
study by Landman et al[20] described the presence of  2 
negative side-effects, but this was insufficient to conclude 
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that there was a causal relationship with device-guided 
breathing.
METHODOLOGICAL QUALITY
In order to compare the studies, we assessed the meth-
odological quality using the criteria as described by van 
Tulder et al[23] (Table 2). The quality of  the study by An-
derson et al. was low; they used an open randomisation 
procedure without any further explanation regarding 
this procedure and blinding[18]. After carefully evaluating 
the studies by Schein et al[9] and Grossman et al[10] several 
methodological questions remained unanswered. It was 
stated in the Schein et al[9] study that the study had a dou-
ble-blind study design[9]. Randomisation was performed 
by a third party and a special technician delivered and 
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  Ref. Study group Period 
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Table 1  Study and patients characteristics
aP < 0.05 vs control. I: Intervention; C: Control; HT: Hypertension; SBP: (Systolic) blood pressure; DBP: Diastolic blood pressure; T2DM: Type 2 diabetes 
mellitus; CVD: Cardiovascular disease; OSA: Obstructive sleep apnea. 
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explained the device and study procedures. Although the 
doctor was not aware of  the group assignment, patients 
had weekly follow-up meetings including blood pres-
sure measurements by that same person. Patients were 
requested not to talk about the specific device with their 
doctor or to other persons who may be participating in 
the study. As the patients saw their doctor very regularly 
it is not unlikely that the doctor became aware of  group 
assignment. Therefore, from a methodological point of  
view, the authors could have opted for another person 
performing the outcome measurements. An alternative 
method would have been to check the success of  the 
blinding procedure. The authors did not explain their 
rationale behind this randomisation procedure. Further-
more, there were several primary endpoints instead of  1 
primary endpoint and 2 secondary endpoints. Also, 5% of  
all blood pressure data were excluded in an unconvention-
al and post-hoc defined ‘end of  treatment period’ analysis. 
Grossman et al[10] did not describe whether treat-
ment allocation was concealed and who performed the 
outcome measurements. Also, data on compliance and 
whether the blinding procedure was a success, were 
not provided. Two patients in the control group started 
lifestyle modification programmes, but analyses without 
these patients did not change the results. 
The Logtenberg, Altena et al[16] and Landman et al[20] 
studies have one important limitation in common: the 
width of  the 95%CI of  the change of  office-measured 
SBP between groups[15,16,20]. These studies were powered 
to detect an absolute reduction of  10 mmHg in SBP. In 
all these studies the limits of  the confidence intervals 
exceeded the boundary of  10 mmHg. The 95%CI in the 
Logtenberg et al[15] and Landman et al[20] studies ranged 
from -2.3 mmHg to 11.7 mmHg, and -6.5 mmHg to 
11.2 mmHg, respectively, with a direction in favour of  
the control group[15,20]. This means that clinically relevant 
disadvantageous effects of  device-guided breathing could 
not be ruled out. For the Altena et al[16] study, the confi-
dence interval ranged from -12.4 mmHg to 3.9 mmHg 
with a direction in favour of  the intervention group[16]. 
Logtenberg et al[15] did not provide data on avoiding co-in-
terventions, whereas Altena et al[16] reported that 1 patient 
in the control group had a change in antihypertensive 
therapy (per-protocol analyses showing the same results). 
HbA1c level was higher in the intervention group of  the 
Landman et al[20] study, but additional analyses in which 
adjustments for age, gender, body mass index and HbA1c 
were done did not relevantly change the results[20]. The 
adjusted differences in SBP and DBP were 1.1 mmHg 
(95%CI: -7.6-9.8, in favour of  the control group) and 3.5 
mmHg (95%CI: -0.4-7.4, in favour of  the intervention 
group), respectively. Finally, the Logtenberg et al[15] and 
Altena et al[16] studies had a single-blind design.
Sample size calculations were described in 4 stud-
ies[9,15,16,20], and lacking in the Anderson et al[18] and Gross-
man et al[10]studies[10,18]. Although Grossman et al[10] men-
tioned that the group size was large enough, they didn’t 
provide a calculation[10]. The Logtenberg study based the 
calculation on mean SBP and standard deviation (SD) in 
their clinic[15]. Altena et al[16] used the mean blood pres-
sure and SD that were observed in the Logtenberg et al[15] 
study. The most conservative and optimal calculation 
was performed in the Landman study, as they based their 
sample size on the highest SD of  the change in SBP in 
the Logtenberg et al[15] (SD 9.4 mmHg) and Altena et al[16] 
(SD 10.9 mm Hg) studies[20]. Comparable to their data 
analysis, Schein et al[9] used an unconventional method for 
the estimation of  their sample  size. The standardised de-
tectable difference was based on a previous study[24] while 
they could have used the change in blood pressure and its 
SD.
DISCUSSION
Out of  the 13 RCTs published, there were only a few 
studies with an acceptable methodological quality. All 
studies had a short follow-up period. In order to exert ef-
fects on cardiovascular morbidity by using device-guided 
breathing, the device has to be used for many months 
and preferably years. None of  the studies investigated 
whether the device could be used for prolonged periods. 
There is 1 meta-analysis, without any involvement of  
the manufacturer, that showed a small beneficial effect 
on blood pressure with unclear clinical relevancy of  us-
ing device guided breathing[8]. As was discussed by the 
authors of  this meta-analysis, the overall effect estimate 
could have been biased due to inclusion of  inadequately 
controlled trials and sponsored studies. In studies with 
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  Criteria Schein[9] Grossman[10] Logtenberg[15] Altena[16] Anderson[18] Landman[20]
  Randomization adequate +/- + + + - +
  Treatment allocation concealed + ? + + - +
  Groups similar at baseline + + + + + +
  Patient blinded +/- +/- + + - +
  Care provider blinded +/- +/- - - - +
  Outcome assessor blinded - ? - - - +
  Co-interventions avoided + +/- ? + ? +
  Compliance acceptable + ? + + + +
  Withdrawal/drop-out rate acceptable + + + + + +
  Timing of outcome assessment similar + + + + + +
  Intention to treat analyses +/- + + + - +
Table 2  Randomized controlled trials with an active control group: methodological quality
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an acceptable methodological quality, no beneficial ef-
fects were seen. Sensitivity analysis showed that studies, 
performed without involvement of  the manufacturer, 
showed no beneficial effects of  device-guided breath-
ing[8]. Since the meta-analysis was published, 1 additional 
study has been completed. This study, which had a suc-
cessful double-blinding procedure and a sham control 
group, showed no beneficial effects and even possible 
adverse events[20]. Unfortunately, the writing group of  the 
AHA guideline on non-pharmacological hypertension 
treatment finished writing the guideline before publica-
tion of  this latest trial. As this latest study has the highest 
level of  evidence, the writing group from the AHA was 
asked to reconsider their recommendation from Class Ⅱ
A, Level of  Evidence B into class Ⅲ, Level of  Evidence 
B (evidence that treatment is not effective)[25]. The com-
mittee responded that they didn’t believe that the recom-
mendation should be changed[26]. Despite the fact that the 
latest study showed possible adverse events, the writing 
group focussed on a small positive general effect estimate 
from the meta-analysis by Mahtani et al[8] and a meta-anal-
ysis that was performed by themselves[4]. This positive 
recommendation by the guideline committee does not 
seem to be in line with the evaluation of  the authors of  
the Mahtani et al[8] study who criticized the methodologi-
cal quality of  most studies and the sponsor involvement 
in the discussion section of  that paper[8]. Since 1 member, 
who was involved in evaluating the topic of  device-guid-
ed breathing for the AHA guideline, previously received 
funding from the manufacturer of  the Resperate® device, 
the response of  the AHA guideline committee is of  po-
tential concern[4]. We agree with Mahtani et al[8] that there 
is a real possibility that bias was introduced in the overall 
effect estimate from combining not adequately control-
led studies and by including studies with a high level of  
sponsor involvement. 
CONCLUSION
We conclude that, based on studies with acceptable 
methodological quality, there is no evidence for a short-
term beneficial effect on blood pressure by using device-
guided breathing. A meta-analysis of  individual patient 
data combining studies with adequate control groups 
should be performed in the near future. Since there are 
no trials, not even uncontrolled, with sufficient follow-up 
on the feasibility and safety of  using the device for many 
months or years, this device cannot safely be advised for 
treating hypertension in daily practice.
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